You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Claims for Patent: 8,633,309

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,633,309

Title:	Nucleoside phosphoramidates
Abstract:	Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
Inventor(s):	Ross; Bruce (El Granada, CA), Sofia; Michael Joseph (Doylestown, PA), Pamulapati; Ganapati Reddy (San Ramon, CA), Rachakonda; Suguna (Twinsburg, OH), Zhang; Hai-Ren (San Jose, CA), Chun; Byoung-Kwon (Robbinsville, NJ), Wang; Peiyuan (Totowa, NJ)
Assignee:	Gilead Pharmasset LLC (Foster City, CA)
Application Number:	13/738,425
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,633,309
Patent Claims:	1. A compound represented by the formula (4): ##STR00037## wherein P* represents a chiral phosphorus atom and wherein the compound is at least 97% of the S.sub.Pstereoisomer represented by the formula (S.sub.P-4): ##STR00038## and not more than 3% of the R.sub.Pstereoisomer represented by the formula (R.sub.P-4): ##STR00039## 2. The compound according to claim 1, wherein the compound is at least 98% of the S.sub.Pstereoisomer represented by the formula (S.sub.P-4) and not more than 2% of the R.sub.Pstereoisomer represented by the formula (R.sub.P-4). 3. The compound according to claim 1, wherein the compound is at least 99% of the S.sub.Pstereoisomer represented by the formula (S.sub.P-4) and not more than 1% of the R.sub.Pstereoisomer represented by the formula (R.sub.P-4). 4. A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable medium. 5. A pharmaceutical composition comprising the compound according to claim 2 and a pharmaceutically acceptable medium. 6. A pharmaceutical composition comprising the compound according to claim 3 and a pharmaceutically acceptable medium. 7. A method of treating a hepatitis C virus infection in a human comprising administering to the human an effective amount of the compound according to claim 1. 8. The method according to claim 7 further comprising administering to the human another antiviral agent. 9. A method of treating a hepatitis C virus infection in a human comprising administering to the human an effective amount of the compound according to claim 2. 10. The method according to claim 9 further comprising administering to the human another antiviral agent. 11. A method of treating a hepatitis C virus infection in a human comprising administering to the human an effective amount of the compound according to claim 3. 12. The method according to claim 11 further comprising administering to the human another antiviral agent.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.